Navigation Links
Symmetry Medical Reports Third Quarter 2008 Financial Results

Increases Full Year Revenue Guidance to a range of $417 Million to $422 Million

Third Quarter 2008 Highlights:

- Record revenue of $112.1 million, up 47.8% over third quarter 2007

- Gross profit of $25.7 million a 126.8% increase compared to the third quarter 2007

- Net income of $0.07 per share compared to a loss of $0.03 per share in the third quarter 2007

- Net income includes unfavorable impact of foreign exchange, tax loss carry forward, a facility closure costs and Sheffield, UK headcount reduction costs

WARSAW, Ind., Nov. 12 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced today third quarter 2008 financial results for the period ended October 4, 2008.

Revenue for the third quarter 2008 was $112.1 million, up 47.8% from $75.8 million reported in the third quarter 2007. Third quarter 2008 revenue included an incremental $4.7 million from SSI and UCA, which was acquired in August 2007; and $14.0 million from the Company's New Bedford, Massachusetts manufacturing facility, which was acquired from DePuy Orthopaedics, Inc. in January 2008. Excluding these acquisitions, the Company achieved organic revenue growth of 23.2% over the third quarter of 2007.

Gross profit for the third quarter 2008 was $25.7 million, an increase of 126.8% from $11.3 million for the third quarter 2007. Gross profit for the third quarter of 2008 was impacted by several unfavorable items which include $0.7 million related to the closure of the Company's Switzerland facility, $0.5 million related to Sheffield headcount reduction and a $0.4 million gross profit reduction in the Company's domestic forging operations as a result of a large press break down. The impact of these unfavorable items more than offset the lower loss experienced at our Sheffield operations of $0.8 million.

Gross margin percentage for the third quarter 2008 was 22.9% compared to gross margin percentage of 14.9% for the third quarter 2007.

Selling, general and administrative expenses were $15.2 million for the third quarter 2008, compared to $9.0 million in the third quarter 2007. The year-over-year increase was driven by $2.3 million from the addition of expenses from the recent acquisitions, $0.9 million from the remaining professional fees and expenses related to the review of accounting irregularities at the Sheffield, UK operating unit and $0.7 million from an increase in restricted stock expense. The remaining increase is a result of increased sales commission expense to support the higher sales levels and general inflation.

Operating income for the third quarter of 2008 was $10.5 million, up 359.9% from $2.3 million for the third quarter 2007. Operating margin for the third quarter 2008 was 9.4%, an increase from 3.0% for the third quarter 2007. In addition to several items in gross profit and SG&A mentioned above, operating income was negatively impacted by continuing operating losses at the Sheffield UK unit.

The third quarter 2008 net income included the unfavorable gross margin items worth $1.6 million or ($0.03) per share, a net unfavorable foreign exchange impact of $2.1 million or ($0.04) per share primarily at our Sheffield, UK operating unit, the impact of recording a full tax valuation allowance on current year losses at the Sheffield, UK operating unit of $1.1 million or ($0.03) per share, and the remaining Sheffield investigation expenses of $0.9 million or ($0.02) per share. Given these items, the net loss at Sheffield was $4.7 million compared to a net loss of $3.2 million in the second quarter of 2008. The Company is beginning to benefit from sales price increases, material efficiencies and the third quarter reduction in headcount at the Sheffield facility showing up in improved operating income.

Net income for the third quarter 2008 was $2.5 million, or $0.07 per diluted share, compared to net income of $(1.1) million, or $(0.03) per diluted share, for the third quarter of 2007. The items noted above decreased net income by $4.1 million, or ($0.12) per diluted share.

The weighted average number of diluted shares outstanding during the third quarter of 2008 was 35,402,097.

Brian Moore, President and Chief Executive Officer of Symmetry Medical, stated, "We have continued to operate at a high level of capacity, with record revenues for the third quarter of 2008. While demand from major orthopaedic customers remained strong through the quarter, which we believe will be sustained through year-end and into 2009, we remain cautious in view of the economic environment. In the face of this challenging environment, we are finding that OEMs are seeking the highest quality and dependability from suppliers which provides Symmetry a major competitive advantage with customers who turn to us for our reliability and global Total Solutions approach."

Mr. Moore continued, "While slower than we originally expected, our Sheffield operation is recovering with narrower losses and greater efficiencies. Our New Bedford instrument facility continues to perform at high levels and we are actively adding OEM customers to that site with shipment to those customers anticipated by the end of the calendar year."

Financial Guidance

The following forward-looking estimates regarding 2008 earnings guidance are based on current market conditions and foreign currency comparisons. Actual results may differ materially, and we refer you to forward-looking statements located at the end of the press release.

For the full year 2008, the Company is increasing revenue guidance to a range of $417 million to $422 million, up from the previously announced range of $410 million to $420 million. This increase is based on current order flow and anticipated customer demand for the remainder of 2008.

For the full year 2008, the Company is adjusting guidance for diluted earnings per share in the range of $0.41 to $0.43, which reflects the third quarter results, additional non-cash foreign exchange impact given current market rates, a higher tax rate, and a delay in the Sheffield operating unit's return to profitability. The Sheffield operating unit incurred a lower operating loss during the third quarter 2008 and recorded operating income in the month of September. However, given the impact of foreign exchange and slower than expected improvements, the Company does not expect the Sheffield unit to reach profitability for the full fourth quarter of 2008 as previously anticipated but does expect that Sheffield will exit the fourth quarter of 2008 at break-even operating income.

Conference Call

Symmetry Medical will host a conference all at 8:00 a.m. ET on November 12, 2008. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate website at The dial-in numbers are (800) 706-7748 for domestic callers and (617) 614-3473 for international. The reservation number for both is 10092834. After the live Web cast, the call will remain available on Symmetry Medical's Web site through February 12, 2009. In addition, a telephonic replay of the call will be available until November 19, 2008. The replay numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 24192002.

About Symmetry Medical Inc.

Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopaedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.

Forward-Looking Statements

Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be "forward-looking statements" that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as "may," "might," "will," "should," "expect," "believe," "anticipate," "plan," "estimate," "intend," and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual outcomes and results could differ materially from our current expectations. We refer you to the "Risk Factors" and "Forward Looking-Statements" sections in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as the Company's other filings with the SEC, which are available on the SEC's Web site at


The Ruth Group

Nick Laudico/Jason Rando



Symmetry Medical Inc.

Fred Hite

Senior Vice President

Chief Financial Officer

(574) 371-2218

Symmetry Medical Inc.

Condensed Consolidated Balance Sheets

October 4, December 29,

2008 2007

---- ----

(In Thousands, Except Per Share Data)



Current Assets:

Cash and cash equivalents $17,791 $12,089

Accounts receivable, net 58,825 42,992

Inventories 62,782 45,353

Refundable income taxes 5,105 6,516

Deferred income taxes 3,437 2,551

Derivative valuation asset 917 2

Other current assets 2,364 2,940

----- -----

Total current assets 151,221 112,443

Property and equipment, net 120,397 100,424

Derivative valuation asset 261 -

Deferred income taxes - -

Goodwill 153,696 141,985

Intangible assets, net of accumulated

amortization 46,800 44,567

Other assets 2,003 1,011

----- -----

Total Assets $474,378 $400,430

======== ========

Liabilities and Shareholders' Equity:

Current Liabilities:

Accounts payable $32,250 $34,518

Accrued wages and benefits 12,133 10,922

Other accrued expenses 4,803 8,096

Income tax payable 6,038 2,394

Derivative valuation liability - 74

Deferred income taxes 352 407

Revolving line of credit 7,477 6,511

Current portion of capital lease

obligations 1,393 2,487

Current portion of long-term debt 15,713 10,900

------ ------

Total current liabilities 80,159 76,309

Deferred income taxes 12,063 12,136

Derivative valuation liability 2,286 1,917

Capital lease obligations, less

current portion 3,603 4,032

Long-term debt, less current portion 126,825 68,500

------- ------

Total Liabilities 224,936 162,894

------- -------

Commitments and contingencies (Note 9)

Shareholders' Equity:

Common Stock, $.0001 par value; 72,410

shares authorized; shares issued

October 4, 2008--35,831; December 29,

2007--35,444) 4 4

Additional paid-in capital 274,994 272,623

Accumulated deficit (32,824) (45,526)

Accumulated other comprehensive income 7,268 10,435

----- ------

Total Shareholders' Equity 249,442 237,536

------- -------

Total Liabilities and Shareholders'

Equity $474,378 $400,430

======== ========

Symmetry Medical Inc.

Condensed Consolidated Statements of Operations

Three Months Ended Nine Months Ended

------------------ -----------------

October 4, September 29, October 4, September 29,

2008 2007 2008 2007

---- ---- ---- ----

(In Thousands, Except Per Share Data)

(unaudited) (unaudited) (unaudited) (unaudited)

Revenue $112,095 $75,823 $323,744 $210,259

Cost of Revenue 86,445 64,511 246,733 172,518

------ ------ ------- -------

Gross Profit 25,650 11,312 77,011 37,741


general, and


expenses 15,165 9,032 44,474 24,713

------ ----- ------ ------

Operating Income 10,485 2,280 32,537 13,028

Other (income)


Interest expense 2,683 1,808 8,300 5,001

Loss on debt




(gain)/loss (972) 1,372 (1,041) 1,356

Other 3,079 (627) 2,581 (1,290)

----- ---- ----- ------

Income (loss)

before income

taxes 5,695 (273) 22,697 7,961

Income tax expense 3,162 814 9,995 2,738

----- --- ----- -----

Net income (loss) $2,533 $(1,087) $12,702 $5,223

====== ======= ======= ======

Net income (loss)

per share:

Basic $0.07 $(0.03) $0.36 $0.15

===== ====== ===== =====

Diluted $0.07 $(0.03) $0.36 $0.15

===== ====== ===== =====

Weighted average

common shares and

equivalent shares


Basic 35,174 35,130 35,161 35,074

Diluted 35,402 35,291 35,354 35,255

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
2. Symmetry Medical Launches New Global Web site
3. Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe
4. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
5. Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility
6. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
7. Facial asymmetry persists despite surgery to correct congenital deformity
8. Symmetry Medical to Expand Malaysian Operations
9. Symmetry Medical Delays 10-K Filing to Complete Review
10. Symmetry Medical Reports Full Year 2007 Financial Results
11. Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008
Post Your Comments:
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Students and parents ... awarded to winners of the Create Real Impact awards. California Casualty is ... help stem the tide of distracted and reckless driving, the number one killer of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD ... benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology ... by a dentist in Gettysburg, PA . From routine visits to cosmetic ...
(Date:11/24/2015)... AZ (PRWEB) , ... November 24, 2015 , ... Young ... 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... and variables that determine which patients are or are not eligible for bariatric surgery. ... a BMI over 40, are more than 100 pounds overweight, or have a BMI ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 Sectra (STO: ... has entered into a multi-year agreement to deploy ... investment will provide the Breast Center a future-proof platform ... (STO: SECT B) announces that Breast Center of ... deploy Breast Imaging PACS in its two freestanding imaging ...
(Date:11/24/2015)...   HeartWare International, Inc . (NASDAQ: HTWR ... technologies that are revolutionizing the treatment of advanced heart ... Doug Godshall is scheduled to present at ... on December 1, 2015 at 3:00 p.m. ET.  The ... New York . . ...
(Date:11/24/2015)... , November 24, 2015 ... of the University of Bern ... Nutrition of the Bern University Hospital "Inselspital" are proud ... develop a novel generation artificial pancreas. Combining a fully ... for diabetic patients with the unequalled accuracy of an ...
Breaking Medicine Technology: